VC: Serenex gain $31M in fourth round



Serenex gain $31M in fourth round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Serenex
Durham, NC

$31M
Fourth

Cornell Capital Partners, Pearl Street Ventures, MC Life Science Ventures and Pac-Link Bio Venture Capital

The money will be used to fuel the clinical development of two cancer products--SNX-1012 and SNX-5422--as well as its work on Heat Shock Protein 90 (Hsp90) inhibitors.

BioVex
Woburn, MA

$22M
Fifth

New Science Ventures

BioVex is working to develop new therapies for cancer and infectious diseases.

Serentis
UK

$20.6M
First

MVM Life Science Partners, Apposite Capital and Novo A/S

The money is being earmarked to push its lead candidates into proof of principle trials and provide the buying power to in-license new drug candidates.

Koronis Pharmaceuticals
Seattle

$20M
Fourth

Pacific Horizon Ventures Asset Management Company

The money will be used to advance its antiviral therapeutics based on Viral Decay Acceleration.

Diatos
France

$12.8M
Fourth

GIMV Credit Agricole Private Equity, InterWest Partners, Innoven Partenaires, Sofinnova Partners and Biotech Fund Flanders

The new injection of funding will allow Diatos to further develop its leading clinical products.

Company Name
Wayne, PA

$8.7M
Second

Safeguard Scientifics

Cellumen will use the funds to complete its management team, further develop its product catalog, continue its CSB platform development, and commercialize its cellular models of disease and cytotoxicity profiling services and products.

CODA Genomics
Laguna Hills, CA

$7M
Third

OVP Venture Partners

CODA develops protein production technology.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.